The treatment being investigated is dapagliflozin propanediol monohydrate, which belongs to a class of drugs known as gliflozins. Participants in the study may receive this medication via oral use, meaning it is taken by mouth. Some participants will receive this early treatment along with telephone counseling, while others will receive standard care provided by the hospital. The study will monitor how well the treatment is accepted and followed over a period of time.

The purpose of the study is to compare the effects of BI 690517 to Spironolactone on kidney function and how blood flows through the kidneys. Researchers will look at Renal Hemodynamics, which refers to how blood moves through the kidney organs, and changes in protein levels in the blood and urine. The study will monitor how these treatments impact Glomerular Filtration Rate, a measurement used to check how well the kidneys filter waste from the blood, over a period of time.

During the study, participants will be observed at different intervals, specifically at 4 weeks and 26 weeks, to track changes in their kidney health and blood flow. Other substances such as Iohexol or Aminohippuric Acid may be used during certain procedures to help measure kidney performance.

The purpose of this research is to evaluate whether injecting these stem cells into the heart muscle is safe for patients with advanced heart failure. The treatment involves a surgical procedure where the cells are injected directly into specific areas of the heart that have been damaged by the previous heart attack. The study will monitor patients for any heart-related complications and track their overall health after receiving the treatment.

During the study, patients will receive the stem cell treatment along with their standard heart care. The research team will perform various tests to check heart function, including echocardiography (heart ultrasound) and magnetic resonance imaging (MRI) scans. Patients will be monitored regularly after the procedure to assess their recovery and any changes in their heart condition.

The purpose of the study is to see if ferric derisomaltose can help reduce the number of deaths related to heart problems and the number of times patients need to be hospitalized due to worsening heart failure. Participants in the study will be randomly assigned to receive either the iron treatment or no iron treatment. The study will monitor participants over a period of time to track their health outcomes, such as hospital visits and overall survival.

Throughout the study, researchers will collect information on various health indicators, including changes in heart failure symptoms and iron levels in the blood. The study aims to provide valuable insights into whether treating iron deficiency with ferric derisomaltose can improve the health and quality of life for people with Chronic Heart Failure.

Participants in the study will receive either the vitamin D and sucrosomial iron combination or the ferric carboxymaltose treatment. The study will last for 24 weeks, during which the effects of these treatments on heart failure symptoms will be monitored. The main focus will be on the distance participants can walk in six minutes, which is a common way to assess physical ability in heart failure patients. Other aspects, such as quality of life and heart function, will also be evaluated.

The study will help determine if the oral combination of vitamin D and sucrosomial iron is a viable alternative to the intravenous iron treatment for improving the health of patients with chronic heart failure and iron deficiency. This research could provide valuable insights into more accessible treatment options for managing these conditions.

Participants in the study will be divided into groups. One group will receive Lokelma along with RAAS inhibitors, while the other group will receive RAAS inhibitors without Lokelma. The study will last for about three months, during which the effectiveness of the treatment will be monitored. The goal is to see if patients can safely increase their dose of RAAS inhibitors, which are important for managing heart failure and chronic kidney disease, by at least 25% compared to their initial dose. This will help determine if Lokelma can help patients better tolerate higher doses of RAAS inhibitors.

Throughout the study, various health parameters will be observed, such as changes in blood pressure and kidney function, as well as the number of hospital visits related to heart failure, hyperkalemia, or impaired kidney function. The study aims to provide valuable insights into how Lokelma can be used to improve the management of heart failure and chronic kidney disease in elderly patients, potentially leading to better health outcomes and quality of life.

Participants in the study will receive either dapagliflozin or a placebo, both taken as oral tablets. The treatment period will last for about three months. Throughout the study, changes in certain health markers will be monitored, such as the levels of a specific protein in the blood that indicates heart stress, known as NT-proBNP. Additionally, the study will assess changes in the participants’ quality of life, heart function, and exercise capacity.

The goal of the study is to see if dapagliflozin can help reduce the symptoms and improve the overall health of people with chronic right heart failure. By participating in this study, researchers hope to gather valuable information that could lead to better treatment options for this condition in the future.

The purpose of the study is to determine if these treatments can reduce the risk of death and hospitalizations related to heart failure. Participants in the study will be randomly assigned to receive either the active medications or a placebo. The study will be conducted over a period of time, with regular check-ups to monitor the participants’ health and response to the treatment. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the active medication or the placebo, to ensure unbiased results.

Throughout the study, participants will take the medications orally in tablet form. The trial aims to provide valuable information on whether these treatments can improve outcomes for patients with chronic heart failure, particularly those with reduced heart function and additional conditions like diabetes. The study is expected to continue until 2028, allowing researchers to gather comprehensive data on the long-term effects of these treatments.

Participants in the study will receive either Digoxin or a placebo, and their progress will be monitored over a period of 24 weeks. During this time, researchers will evaluate the participants’ heart function and overall physical capacity. This will involve tests such as measuring peak oxygen consumption and using echocardiography, which is an ultrasound of the heart, to assess how well the heart is working.

The study will also look at other health outcomes, such as the occurrence of hospitalizations, changes in certain blood markers, and overall quality of life. By the end of the study, the researchers hope to better understand the role of Digoxin in managing heart failure and improving patients’ health and well-being.

The purpose of the study is to investigate how Vericiguat affects patients with heart failure, particularly those who have a device called the CardioMEMS HF System implanted. This device helps monitor heart function. Participants in the study will receive either Vericiguat or a placebo, and the effects on their heart condition will be observed over a period of time. The study will look at how Vericiguat impacts certain heart-related measurements, such as the pressure in the pulmonary artery, which is a blood vessel that carries blood from the heart to the lungs.

Throughout the study, participants will take the medication orally, and the treatment period will vary depending on the dosage. The study aims to provide valuable information on the potential benefits of Vericiguat for people living with heart failure, helping to improve their quality of life and manage their condition more effectively.

Participants in the study will receive either Colchicine or a placebo, which is a substance with no active medication. Colchicine is a medication that is often used to treat inflammation. The study will be conducted in a way that neither the participants nor the researchers know who is receiving the actual medication or the placebo, ensuring unbiased results. The trial will last for a period of time during which the effects of the medication on blood vessel function and inflammation will be closely monitored.

The study aims to provide insights into the safety and effectiveness of Colchicine in improving heart and blood vessel health in patients with chronic heart failure and CHIP mutations. By understanding these effects, researchers hope to find better ways to manage heart failure and improve the quality of life for those affected by this condition.

The purpose of the study is to evaluate how effective Meldonium and personalized physical activities are in treating patients with this type of heart failure. Participants will receive Meldonium and follow a personalized physical activity plan. The study will observe changes in how well participants can tolerate physical activity, which will be assessed through a test that measures how much oxygen the body uses during exercise.

The study will take place over a period of time, and participants will be monitored to see how their condition responds to the treatment. The goal is to understand if Meldonium, along with individualized physical activities, can improve the health and quality of life for people living with chronic heart failure with preserved ejection fraction.

The purpose of the study is to evaluate the tolerability of this starting dose in participants with chronic heart failure. Participants will begin with a 5 mg dose of vericiguat and continue for a period of two weeks. During this time, researchers will monitor the participants to ensure they can complete the two-week course without stopping the medication due to side effects or experiencing moderate to severe low blood pressure, known as hypotension.

The study will also observe any adverse effects, which are unwanted symptoms or reactions, that may occur between the start and end of the two-week period. The goal is to ensure that participants can continuously take the medication or resume it if there is any temporary interruption. This trial aims to provide valuable information on the safety and tolerability of vericiguat for individuals with chronic heart failure with reduced ejection fraction.

Participants in the study will be randomly assigned to receive either the AZD5462 tablet or a placebo, which looks like the real medication but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased. The study will last for about 24 weeks, during which participants will take the medication orally.

Throughout the study, participants will have regular check-ups to monitor their heart health and overall well-being. These check-ups will include various tests to measure changes in heart function and health status. The goal is to see how AZD5462 affects heart failure symptoms and to determine the best dose for treatment. The study aims to provide valuable information that could lead to improved treatments for people living with chronic heart failure.

Participants in the study will take dapagliflozin to see if it helps increase the amount of sodium removed from their bodies. The study will monitor how the medication affects the body’s ability to get rid of sodium through urine and peritoneal dialysis over a period of time. This is important because managing sodium levels can help improve symptoms in patients with heart failure.

The study will involve a group of patients who will be observed to see how their bodies respond to the treatment. The goal is to determine if dapagliflozin can help improve the management of sodium levels in patients with heart failure who are also undergoing peritoneal dialysis. This research could provide valuable insights into better treatment options for individuals with this challenging condition.

Participants in the study will receive either the Trimeductan MR medication or a placebo, which looks like the medication but does not contain the active ingredient. The study will monitor participants over a period of time to observe any changes in their health, particularly focusing on the time it takes for participants to be hospitalized or experience serious health events related to their heart condition. The study aims to gather information on how the medication might improve heart function and overall health outcomes for those with HFpEF.

Throughout the study, various health indicators will be measured, including heart function and levels of certain substances in the blood that are linked to heart health and inflammation. These measurements will help researchers understand the potential benefits of Trimeductan MR for people with HFpEF. The study is expected to continue until the end of 2027, providing valuable insights into the treatment of this heart condition.

The study involves three groups of participants. One group will receive a low dose of CDR132L, another group will receive a higher dose, and the third group will receive a placebo. The treatment is given through an intravenous infusion, which means it is administered directly into the bloodstream. Participants will receive three doses, each given 28 days apart. The study will monitor changes in heart function and overall health over a period of time to determine the impact of the treatment.

Throughout the study, participants will undergo various health assessments, including heart imaging tests and blood tests, to track their progress. The goal is to see if CDR132L can help improve heart function and reduce symptoms associated with heart failure after a heart attack. The study will also keep track of any side effects or health changes experienced by participants to ensure the treatment is safe.